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A Little Bit Pregnant: Modeling How the Accurate Detection of Pregnancy
Can Improve HIV Prevention Trials
Abstract

The prevalence of unplanned pregnancies contributes to the methodological challenges of human
immunodeficiency virus (HIV) prevention trials. In this paper, the authors discuss the incidence of
pregnancy, including chemical pregnancy, and how the different methods of pregnancy diagnosis could affect
the statistical power and calculated outcomes of HIV prevention trials. Study sample size inflation factors are
estimated to aid in the design of clinical trials.The authors used published data of women attempting
pregnancy as well as data from HPTN 055 (www.HPTN.org/research_studies/hptn055.asp) to estimate the
percentage of early study discontinuation that would be associated with 3 diagnostic methods for pregnancy
in a hypothetical clinical trial. They classified chemical pregnancies as false-positive pregnancy tests and
showed the sample size adjustment that would be necessary in clinical trial design because of the early
discontinuations associated with pregnancy. There is a greater than 3-fold difference in the number of falsely
positive pregnancy tests that will be detected, depending upon the diagnostic method used. The number of
incident pregnancies may render HIV prevention trial sample sizes inadequate by as much as 50%. Pregnancy
prevention and precise pregnancy diagnosis are critical to the statistical power and integrity of HIV
prevention trials.
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The prevalence of unplanned pregnancies contributes to the methodological challenges of human immunodeﬁciency virus (HIV) prevention trials. In this paper, the authors discuss the incidence of pregnancy, including
chemical pregnancy, and how the different methods of pregnancy diagnosis could affect the statistical power and
calculated outcomes of HIV prevention trials. Study sample size inﬂation factors are estimated to aid in the design
of clinical trials.The authors used published data of women attempting pregnancy as well as data from HPTN 055
(www.HPTN.org/research_studies/hptn055.asp) to estimate the percentage of early study discontinuation that
would be associated with 3 diagnostic methods for pregnancy in a hypothetical clinical trial. They classiﬁed
chemical pregnancies as false-positive pregnancy tests and showed the sample size adjustment that would be
necessary in clinical trial design because of the early discontinuations associated with pregnancy. There is
a greater than 3-fold difference in the number of falsely positive pregnancy tests that will be detected, depending
upon the diagnostic method used. The number of incident pregnancies may render HIV prevention trial sample
sizes inadequate by as much as 50%. Pregnancy prevention and precise pregnancy diagnosis are critical to the
statistical power and integrity of HIV prevention trials.
clinical trials as topic; contraception; HIV; pregnancy; primary prevention

Abbreviations: hCG, human chorionic gonadotropin; HIV, human immunodeﬁciency virus.

screening women at high risk of pregnancy, and in part
because both HIV and pregnancy originate from the same
vector, incident pregnancies have materialized as a significant concern within HIV prevention trials. In this paper, we
discuss the problem that the diagnosis of pregnancy within
HIV prevention trials presents, the different methods of diagnosing pregnancy, and the impact that the different methods of pregnancy diagnosis have on trial outcomes.
Diagnosis of an incident pregnancy during an HIV prevention trial has repercussions beyond the known social,
health, and economic consequences that unplanned pregnancies have in high-risk populations outside the clinical
trial setting. The pregnant state may affect investigational
drug use or efficacy and the virulence of HIV, which in turn
may complicate trial outcomes (3, 4). The decreased use of
investigational product that accompanies these pregnancies
results in differential product/placebo exposure in the 2 trial

Rates of human immunodeficiency virus (HIV) infection
in women are steadily increasing; according to the World
Health Organization, 17.5 million women worldwide were
infected with HIV in 2005. Vaginal microbicides and other
pharmaceuticals such as preexposure prophylaxis regimens
and vaccines are in development to curb HIV acquisition in
vulnerable populations, including sexually active women of
reproductive age (1). Pregnancy is another outcome that can
result from sexual activity in this same population of
women. Despite the fact that plans to become pregnant
are exclusionary, the pregnancy rate in HIV prevention trials
ranges from 23 to 70 per 100 woman-years (2). The prevalence of pregnancy in these trials has exceeded scientists’
expectations and has the potential to undermine study results because most trials require that women who become
pregnant stop using investigational drugs to avoid fetal exposure. In part because there is no ‘‘gold standard’’ for
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arms, increased bias, and decreased statistical power. This
decrement in statistical power comes from 2 sources: 1) the
censored observations reduce the total number of participants left at risk for the event under study, and 2) in an
intention-to-treat analysis, the effect size decreases because
pregnant women who stop using the investigational product
have a likelihood of seroconversion comparable to that of
the control group. Some microbicides have contraceptive
efficacy, so participants may expect reduced fertility while
using a microbicide. The comparator arm may not have the
same, or any, contraceptive efficacy, which could lead to
different durations of study participation and even different
rates of seroconversion between the 2 groups (3–6). The
diagnosis of pregnancy during a clinical trial is not trivial,
so how is it best made?
Several tools are available to diagnose pregnancy: the
level of human chorionic gonadotropin (hCG) in the serum,
the presence of hCG in the urine (through either highsensitivity or low-sensitivity tests), pelvic ultrasound (not
routinely available in the developing world), and a missed
menstrual period. These diagnostic methods may detect
pregnancy at different stages of progression, and not all
pregnancies progress to delivery of a baby.
Clinical investigators have options regarding how to best
diagnose pregnancy. The choice of test might be based on
availability or cost, but the impact that the timing and accuracy of the pregnancy diagnosis may have on study participation should also be considered. With the hope of
minimizing theoretically poor outcomes, many trials institute frequent pregnancy testing with the goal of early detection of pregnancy so that participants can stop using the
investigational product early and for the duration of pregnancy. While this approach would appear to be appropriately cautious, the reality is that the results of many of these
positive pregnancy tests do not indicate the beginning of
a true clinical pregnancy but instead are chemical pregnancies characterized by a transient rise in the pregnancy
hormone level only.
The term chemical pregnancy is used to describe a transiently positive hCG level not associated with the development of an embryo or even a gestational sac. With the
advent of high-sensitivity urine pregnancy tests in the
1980s, early diagnosis of pregnancy is now widely possible.
A pregnancy test can be positive as early as the first days of
the approximate time of implantation or when traces of hCG
are detectable in the maternal serum. It has been established
that as many as 25% of pregnancies fail even before the
woman has any subjective indication that she is pregnant,
that is, before she misses her menstrual period (7–9) or has
symptoms of pregnancy (10).
In the general population, most chemical pregnancies go
unrecognized. Chemical pregnancies are diagnosed under
active monitoring for pregnancy only if hCG levels are
tested prior to a missed menstrual period. The American
Society of Reproductive Medicine and the Society for
Assisted Reproductive Technology distinguish chemical
pregnancies from clinical pregnancies, which include spontaneous abortions. The transient rise in hCG that characterizes a chemical pregnancy is distinct from the widely
recognized outcomes of a clinical pregnancy, which include

Table 1. Frequency of Pregnancy Outcomes in Population A:
Women Attempting Pregnancy According to 3 Longitudinal Trials in
the United States and Chinaa
Wilcox
et al. (7)

Pregnancy
Outcome

No.
Total conceptions
Chemical
pregnanciesc

b

%

198
44

Zinaman
et al. (8)
No.

%

116
22

15

Wang
et al. (9)
No.

%

587
13

152

Total
No.

%

901
26

210

23

Abortions

18

9

21

18

49

8

89

10

Deliveries

135

68

79

68

373

63

587

65

12

2

14

2

Otherd

1

0.5

1

0.8

a
Percentages may not add to 100% because of dropout/loss to follow-up or
an undetermined pregnancy outcome at the study’s conclusion.
b
Total conceptions with a known outcome.
c
The term chemical pregnancy describes a transiently positive human
chorionic gonadotropin level not associated with the development of an embryo
or even a gestational sac.
d
Includes ectopic pregnancies, molar pregnancies, and induced abortions.

spontaneous and induced abortions, ectopic pregnancy, and
delivery. In the absence of routine use of ultrasound, a chemical pregnancy could be defined by the combination of a low
peak in hCG (<100 mIU/mL), rapid fall in urinary or serum
hCG concentration, and lack of substantial delay in onset of
the next menstrual period to help differentiate this entity
from a clinical pregnancy (7, 9, 11).
In this paper, we demonstrate that, given the prevalence of
chemical pregnancies, differential detection of chemical and
clinical pregnancies has important implications for clinical
trials. To raise consciousness about this issue, and to aid in
future protocol development, we modeled the ways in which
different methods of pregnancy diagnosis could affect the
statistical power and integrity of HIV prevention trials. We
then estimated inflation factors for study sample size to provide a metric by which to compare the impact of the different diagnostic methods on clinical trials.

MATERIALS AND METHODS

We utilized 2 different sources to calculate the prevalence
of the different possible outcomes from a positive hCG test.
Three previously published longitudinal studies of women
attempting pregnancy (7–9) provided information on a total
of 939 women, 2,700 cycles, and 901 total conceptions with
known outcomes (population A). The combined data for the
different pregnancy outcomes from these trials are shown in
Table 1. In summary, all women in these trials collected and
stored daily urine samples while attempting pregnancy, and
they were instructed to present for care if a pregnancy was
suspected. The urine samples were later assessed by using
quantitative hCG tests, and outcomes were correlated with
the presence or absence of clinical pregnancy during each
cycle. These 3 trials illustrate the concept of chemical pregnancies by showing that hCG can be detected in urine during
cycles when a pregnancy was never suspected.
Am J Epidemiol 2009;169:515–521
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Table 2. Frequency of Pregnancy Outcomes in Population B:
Women Avoiding Pregnancy in the HPTN 055 Trial in South Africa
Pregnancy Outcome

Total conceptions
Chemical pregnanciesa,b

No.

%

105
18

17

Abortions

55

53

Deliveriesd

32

30

c

a

The term chemical pregnancy describes a transiently positive
human chorionic gonadotropin level not associated with the development of an embryo or even a gestational sac.
b
Pregnancy test positive for 30 days.
c
Pregnancy test positive for 31–180 days.
d
Pregnancy test positive for 181 days.

Estimates of pregnancy outcomes for women avoiding
pregnancy (population B) were derived from the HPTN
055 HIV Prevention Preparedness Trial (12) and are shown
in Table 2. HPTN 055 is a prospective cohort study initiated
to prepare sites for implementation of HPTN 035, a phase
3 safety and effectiveness study of 2 vaginal microbicides to
prevent HIV. The study was conducted at 2 HPTN study
sites in South Africa. Women were followed for up to
12 months, and HIV seroconversion was the primary outcome. Study participants were asked to avoid pregnancy for
the trial duration even though no drug was tested. Details
regarding the specific populations enrolled in this longitudinal cohort have been published previously (13). Most
women (83% by self-report) were using a contraceptive
method. The most common were injectable methods
(32.7%) and male condoms (32.4%), followed by oral contraceptives (15.0%) and withdrawal or the rhythm method
(13.6%) (2). Participants reported to the study site monthly
for sexually transmitted infection and pregnancy testing.
Pregnancy data were recorded as the number of consecutive
months of positive urine hCG concentrations (or ‘‘pregnancy period’’).
We chose 3 protocols for diagnosing pregnancy: 1)
monthly urine pregnancy tests, 2) monthly pregnancy tests
followed by a confirmatory pregnancy test at a 1-week interval should the initial test be positive, and 3) pregnancy
tests following missed menses only.




Protocol 1 tests each study participant monthly by calendar day, regardless of timing in the menstrual cycle.
Monthly pregnancy tests will detect a positive hCG concentration as early as 26 days after the last menstrual
period to as late as 42 days after the last menstrual period
(the most advanced gestation detectable given a negative
test in the prior month) depending upon menstrual cycle
length and the timing of conception.
Protocol 2 adds a follow-up test at a 1-week interval to
protocol 1. We chose this option based on how the literature helps to distinguish between a chemical and clinical
pregnancy (7, 10, 14–16). On the basis of longitudinal
data, very few chemical pregnancies still show detectable
hCG levels 1 week after the expected menstrual period,
and the vast majority of clinical pregnancies can be de-
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tected by 1 week after an expected menstrual period is
missed. Of 40 women who had a chemical pregnancy (7),
only 8 (20%) experienced a menstrual cycle lasting longer
than 35 days (approximately 1 month plus 1 additional
week). Although data on menstrual cycle lengths demonstrate variability both within and among women (15, 17),
28 days is considered the population-average cycle
length, and when women present with an hCG result of
100 mIU/mL or less, hCG levels decline by an average of
88%–90% by 7 days from initial detection (11). This decrease would result in an hCG level of 10 mIU/mL by the
second hCG test—a level too low to be detected by highsensitivity urine pregnancy tests. Therefore, we extrapolated that the majority of women (80%) with a chemical
pregnancy will have a negative urine hCG test result or
will have resumed their menstrual cycle by 1 week after
an initially positive pregnancy test.
Protocol 3 uses a woman’s missed menstrual period as the
indication for pregnancy testing. Since 97% of clinical
pregnancies will have implanted by 7 days after the first
day of the next expected menstrual period (14), a negative
pregnancy test at 1 week after a missed menstrual period
will exclude most clinical pregnancies.

Using the trends of hCG positivity for both chemical and
clinical pregnancy outcomes (7, 14), we calculated the positive predictive values for detecting a clinical pregnancy for
these 3 diagnostic algorithms. In protocol 1, the positive
predictive value is equal to the proportion of clinical pregnancies detected divided by the total positive hCG tests. In
protocol 2, the total number of positive hCG tests detected is
minus 80% of the chemical pregnancies, while the clinical
pregnancies detected remain constant. The denominator of
the positive predictive value in protocol 3 is calculated by
subtracting 3% of the clinical pregnancies (since 3% of
clinical pregnancies are not yet diagnosed by 1 week after
the expected missed menstrual period) and adding the 20%
of chemical pregnancies that would still be detected by
testing at this time.
We then modeled the annual rates of the reproductive
outcomes for women in a hypothetical study population.
Combining the 2 different population-based pregnancy data
estimates, we calculated the proportion of pregnancies
that would be detected by the 3 diagnostic tests by estimating the proportion of positive hCG results that would
be detected by that test out of the total known positive
hCG results in the studies. Table 3 shows the percentage
of chemical pregnancies, ‘‘false positives’’ in this setting,
that would be detected in the population by each diagnostic
test. We assumed that annual pregnancy rates would range
from 10% to 60% depending on whether or not contraception
is used.
We computed an inflation factor, shown in Table 3, that
can be utilized to ensure adequate statistical power of the
trial. For a prespecified pregnancy rate, denoted as Pr(pregnancy), the proportion of these pregnancies that would be
detected by each protocol (protocols 1–3), described as
Pr(Detecting the Pregnancy|protocol j), is used to determine
what fraction of the total number of study subjects would be
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Table 3. Increase in Sample Size Necessary to Adjust for the Combined Effect of Pregnancy
Incidence and Method of Pregnancy Diagnosis
Inﬂation Factorb for a Given
Pregnancy Rate

Pregnancies
Detecteda
Diagnostic Test
No.

%

10% Pregnancy
Incidence

25% Pregnancy
Incidence

60% Pregnancy
Incidence

Monthly

901

100

1.10

1.33

2.50

þ1 week

733

81

1.09

1.25

1.95

Menses

712

79

1.09

1.25

1.95

Monthly

105

100

1.10

1.33

2.50

þ1 week

91

86

1.09

1.27

2.07

Menses

88

83

1.09

1.26

1.99

Three trials (7–9)

HPTN 055 trial sites

Abbreviation: HPTN, HIV Prevention Trials Network.
Number of positive human chorionic gonadotropin (hCG) concentrations detected with this
test/known positive hCG levels in this population.
b
Inﬂation factor ¼ 1/[1  (proportion of pregnancies detected) 3 (proportion of true pregnancies)].
a

censored because of the diagnosis of pregnancy, Cj. For
protocol j ¼ 1, 2, 3, the proportion censored is

Cj ¼ Pr Detecting the Pregnancyj protocol j

3 Pr Pregnancy :
The inflation factor is then computed as 1/(1  Cj) and can
be used to multiply by the originally calculated sample size

to assure that the trial accounts adequately for attrition due
to pregnancy. This method of sample size adjustment conservatively adjusts for periods of time when pregnant participants are not using the investigational product by
assuming that they are censored from the study for its
duration.
Estimates of the total days of avoidable fetal exposure
shown in Table 4 are conservative assuming the lowest

Table 4. Estimated Exposure Time in a Hypothetical Study of 1,000 Women, Half Randomized to the Active Treatment Arm of a Human
Immunodeﬁciency Virus Prevention Trial
% hCG Positive
That Are
Clinical
Pregnancies
(True Positives)

% hCG Positive
That Are
Chemical
Pregnanciesa
(False Positives)

Avoidable Time
not Using the
Investigational
Product/False-Positive
hCG (Weeks)

1: Monthly

77–83

17–23

4

48

0

2: þ1 week

94–96

4–6

4

12

7

3: Menses

98–99

1–2

4

4

12

1: Monthly

77–83

17–23

4

116

0

2: þ1 week

94–96

4–6

4

32

7

3: Menses

98–99

1–2

4

12

12

1: Monthly

77–83

17–23

4

276

0

2: þ1 week

94–96

4–6

4

72

7

3: Menses

98–99

1–2

4

24

12

Diagnostic
Protocol

Total Person-Weeks
not Using the
Investigational
Productb

Estimated Amount
of Avoidable
Fetal Exposure
(Days/Fetus)

Assuming a pregnancy prevalence
of 10% or 50 conceptions

Assuming a pregnancy prevalence
of 25% or 125 conceptions

Assuming a pregnancy prevalence
of 60% or 300 conceptions

Abbreviation: hCG, human chorionic gonadotropin.
The term chemical pregnancy describes a transiently positive human chorionic gonadotropin level not associated with the development of an
embryo or even a gestational sac.
b
Total person-weeks not using the investigational product ¼ number hCG positive 3 proportion false positive 3 time not using the product
assuming retention in the trial with monthly visits (4 weeks).
a

Am J Epidemiol 2009;169:515–521

Pregnancy in HIV Prevention Trials

519

Table 5. Positive Predictive Valuesa for Diagnosing Pregnancy
Test Type Used to Diagnose Pregnancy
Population

Protocol 1:
Monthly hCGb

Protocol 2:
Monthly/Weeklyc

Protocol 3:
Missed Mensesd

Literature-based estimates of
women attempting pregnancy

691/901 ¼ 77%

691/733 ¼ 94%

691/712 ¼ 97%

87/105 ¼ 83%

87/91 ¼ 96%

87/88 ¼ 99%

HPTN 055 trial

Abbreviation: HPTN, HIV Prevention Trials Network.
Positive predictive value ¼ clinical pregnancies detected with the speciﬁed diagnostic
method/total human chorionic gonadotropin (hCG)–positive tests captured by using that diagnostic method.
b
Monthly hCG tests based on calendar day irrespective of menstrual cycle.
c
Monthly hCG tests with a conﬁrmatory test in 1 week if the initial test is positive.
d
An hCG test conducted 1 week after missed menses only.
a

estimate for false-positive tests (17%), which translates into
the largest possible number of clinical pregnancies. The
estimates for person-time not using the investigational product due to chemical pregnancies assumes the highest (23%)
estimated rate.
RESULTS

The positive predictive values, shown in Table 5, demonstrate the likelihood that a test will diagnose a clinical pregnancy and not misclassify a chemical pregnancy. The
positive predictive values depend on the prevalence of clinical pregnancies in the population.
The modeled HIV prevention trial is shown in Figure 1.
The algorithm demonstrates how the study outcomes are
affected by 1) the number of pregnancies detected by each
diagnostic tool, 2) the prevalence of the type of pregnancy
(chemical vs. clinical) detected, and 3) the population’s use
or nonuse of contraceptives. In this figure, the percentage of
pregnancies detected refers to those detected at that visit by
that diagnostic tool. Any clinical pregnancies not detected
would be noted at a later visit. The number of pregnancies
detected by the different diagnostic methods varies because of
possible resolution of chemical pregnancies, normal variation
in menstrual cycle lengths, and variation in the rate of decline
of hCG concentration. Therefore, although nearly 100% of
pregnancies are detected by performing monthly pregnancy
tests (protocol 1), a significant proportion (17%–23%)
would be chemical pregnancies. In contrast, fewer falsepositive (chemical) pregnancies are identified when the
monthly pregnancy test is followed up with a confirmatory
test after 1 week (protocol 2). With this testing strategy, the
percentage of chemical pregnancies would range from 2% to
4%. When pregnancy tests are performed only after the expected menses is missed (protocol 3), proportionally more of
these pregnancies are considered clinical because the percentage of chemical pregnancies is reduced to 1%–2%.
Table 3 shows how a clinical trial will be affected by
varied pregnancy prevalences. The sample size inflation
factor is the factor by which the initial sample size would
have to be multiplied to achieve the appropriate statistical
power given the pregnancy prevalence associated with each
Am J Epidemiol 2009;169:515–521

diagnostic tool. The inflation factor is designed to help correct for the effect of censoring pregnant participants. For
example, in a protocol that uses monthly pregnancy tests
and requires enrollment of 1,000 women to demonstrate
a difference in HIV seroconversion between the intervention
and control arms of a trial, the inflation factor would increase the target enrollment to 1,100–2,500 once pregnancy
prevalence is accounted for. Table 4 illustrates the effect that
pregnancy prevalence and method of diagnosis have on exposure time in our modeled trial of 1,000 women. For the
sake of comparison, we display, for each pregnancy diagnosis method, the number of days that each fetus would be
exposed to an investigational drug.
DISCUSSION

Despite the age-old saying, the diagnosis of pregnancy is
not binary: women can be a little bit pregnant. In this analysis, we classified detection of a chemical pregnancy as
a false-positive pregnancy test—something that one would
prefer to avoid in clinical trials. Early detection of clinical
pregnancies, which we classified as true-positive tests,
should be optimized in clinical trials. The data put forth
in this paper underscore the varied pregnancy outcomes
that can occur because of the natural history of a positive
hCG test.
The use of highly sensitive pregnancy tests has highlighted, in effect generated, the high prevalence of chemical pregnancies in the population. In the HIV prevention
trial setting, a positive pregnancy test usually results in
a women either being withdrawn from the remainder of
the trial or discontinued from the investigational product
until the pregnancy has ended, which has ethical consequences. The diagnosis of pregnancy is not untroubling
for many women, and a false-positive pregnancy test
may result in unnecessary stress. The methodological consequence of such diagnoses is a decrease in exposure-time
to the investigational product, resulting in a deceased
effect-size in an intention-to-treat analysis and/or censoring, which leads to a reduction in the statistical power of
the trial to demonstrate a difference in HIV seroconversion
between the intervention and control arms. The population
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Nonpregnant Women Enrolled in a
Vaginal Microbicide Trial
(hCG Negative)

Randomized to
Placebo

Randomized to
Microbicide

Monthly Pregnancy
Testing

Inflation
Factor
1.10–2.50

Monthly
Pregnancy
Testing
Followed by a
Confirmatory
Test at 1 Week

Inflation
Factor
1.09–2.07

Pregnancy Tests
Conducted When a
Menstrual Period Is
1 Week Late

Inflation
Factor
1.09–1.99

Figure 1. Three different methods of pregnancy diagnosis and the corresponding impact on the trial sample size required to demonstrate an
effect. The chemical pregnancy percentages vary because a spot highsensitivity urine pregnancy test can detect a pregnancy that resulted from
ovulation any time between 10 and 25 days prior, with a more advanced
pregnancy being less likely to be chemical. The range in each inﬂation
factor is due to the variation in pregnancy rates, as shown in Table 3. The
term chemical pregnancy describes a transiently positive human chorionic gonadotropin (hCG) level not associated with the development of
an embryo or even a gestational sac. Inﬂation factor ¼ 1/[1  (proportion
of pregnancies detected) 3 (proportion of true pregnancies)].

urgently needs methods of HIV prevention: we cannot afford falsely negative studies.
Our analysis has several limitations. Using the longitudinal trials that defined the entity of chemical pregnancies,
we estimated the chemical pregnancy rate to be 23% in the
general population, ranging from 15% to 25%. Although
the definition of a chemical pregnancy is somewhat different in each of the 3 trials, we chose to combine the data sets
to achieve more stable estimates. To moderate this limitation, we have provided ranges of the impact of the different
pregnancy outcomes. Given the estimated chemical pregnancy rate of 17% in HPTN 055, we have at best over-

estimated the impact of chemical pregnancies in clinical
trials, which results in more conservative inflation factors.
Another limitation is that our estimates of the pregnancy
outcomes in HPTN 055 depend on the accuracy of the reported ‘‘pregnancy periods.’’ These periods were calculated
by considering the number of consecutive months with positive hCG tests. Finally, we used data on the rate at which
hCG rises and falls to estimate the prevalence of detectable
chemical pregnancies at different time points. Doing so
required the use of point estimates, which may overestimate
or underestimate the positive predictive values of our diagnostic tests.
Even with these limitations in mind, we have shown that
the manner in which pregnancy is defined has implications
for clinical trials. Because of overlap in the populations at risk
of HIV and the populations at risk of pregnancy, the diagnosis
of pregnancy within an HIV prevention trial has many possible ramifications. If such a diagnosis is made outside of the
usual mode of clinical care (e.g., random monthly testing),
women may begin to mistakenly associate the investigational
product with the diagnosis of a miscarriage instead of a chemical pregnancy (an event that would not have been evident to
that woman in more common life circumstances). By taking
the pregnancy diagnosis out of the context of the menstrual
cycle and using monthly tests, we are in fact redefining the
diagnosis of pregnancy, which will introduce new bias.
The effect that pregnancy has on the HIV prevention
regimen is unknown with respect to safety, acceptability,
or effectiveness. It is possible that becoming pregnant itself
results in a differential risk of HIV acquisition. A disparate
risk of pregnancy in the arms of the trial, compounded with
a possible differential risk of HIV acquisition in pregnant
women, could result in biased trial results. A woman’s attitude toward her pregnancy may modify her sexual risk behaviors as well as her adherence and compliance behaviors
within the clinical trial.
Clearly, the best way to avoid the problems associated with
incident pregnancies in clinical trials is to provide highly
effective contraceptives for women considering enrollment
in an HIV prevention trial, and throughout the trial (18).
The data in Tables 3 and 4 underscore how effective contraception helps to keep the impact of pregnancy low. Although
the most effective methods of contraception approximate success rates of 100% (19), pregnancies may still occur in these
trials if less-effective methods are used or if methods are used
incorrectly. Furthermore, routine use of specific contraceptive
methods may not be a practical requirement of these trials
given the communities in which they are being conducted. If
highly effective methods are not culturally acceptable in the
regions where HIV is most prevalent, investigators may have
little choice but to sacrifice contraceptive efficacy in favor of
high rates of seroconversion.
Short of eliminating pregnancy altogether in these trials,
uniform definitions of pregnancy can be met and incorporated into the protocol. Baseline information about community pregnancy outcomes would provide useful data to
extrapolate effects of the drug, or even study participation,
on pregnancy outcomes. To help curtail the number of falsepositive pregnancies, we advocate a diagnostic method that
avoids monthly pregnancy tests and instead adheres to
Am J Epidemiol 2009;169:515–521
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a clinical standard of care by using a missed menstrual
period or symptoms of pregnancy as the trigger to perform
a test. This method may result in delayed pregnancy diagnosis and more time using the investigational product for
pregnant women; however, given the fact that organogenesis
does not begin until 5–6 weeks after the last menstrual period, the increased exposure of 12 or fewer days may be
acceptable in the setting of reassuring reproductive toxicity
studies. If the specifics of the study population suggest that
clinical parameters are too unreliable, perhaps the scheduled
monthly pregnancy test can be confirmed by a second test
a week later and the woman not diagnosed as being pregnant
until that time. As shown in Table 4, this approach would
have the advantage of minimizing exposure of the developing fetus to the investigational product.
In this paper, we present estimates from the literature of
the different pregnancy outcomes for women who were attempting pregnancy and compare them to those who are
supposed to be avoiding pregnancy in an HIV prevention
preparedness trial. In addition to the prevalence of chemical
pregnancies, we also call attention to the striking number
(53%) of pregnancies in HPTN 055 that ended before
25 weeks of gestation. Whether these abortions are spontaneous or induced, this trial highlights the poor pregnancy
outcomes that this population suffers. Improving reproductive outcomes, in addition to combating the HIV epidemic,
is of paramount public health importance.
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